The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis

Popescu V(2015)What drives MRI-measured cortical atrophy in multiple sclerosis? Mult Scler 21 1280-1290

Klaver R(2009)Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study J Neurol Sci 282 112-119

Voorn P(2013)Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years AJNR Am J Neuroradiol 34 1931-1939

Horakova D(2008)Gray matter atrophy in multiple sclerosis: a longitudinal study Ann Neurol 64 255-265

Dwyer MG(2020)Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis Mult Scler 26 312-321

Havrdova E(2014)Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage J Neurol Neurosurg Psychiatry 85 851-858

Zivadinov R(2018)Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis Neurology 90 e1324-e1332

Bergsland N(2003)Regionally localized thinning of the cerebral cortex in schizophrenia Arch Gen Psychiatry 60 878-888

Dolezal O(2002)Regional and progressive thinning of the cortical ribbon in Huntington’s disease Neurology 58 695-701

Fisher E(2014)Large-scale evaluation of ANTs and FreeSurfer cortical thickness measurements Neuroimage 99 166-179

Popescu V(2015)What drives MRI-measured cortical atrophy in multiple sclerosis? Mult Scler 21 1280-1290

Klaver R(2009)Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study J Neurol Sci 282 112-119

Voorn P(2013)Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years AJNR Am J Neuroradiol 34 1931-1939

Horakova D(2008)Gray matter atrophy in multiple sclerosis: a longitudinal study Ann Neurol 64 255-265

Dwyer MG(2020)Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis Mult Scler 26 312-321

Havrdova E(2014)Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage J Neurol Neurosurg Psychiatry 85 851-858

Zivadinov R(2018)Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis Neurology 90 e1324-e1332

Bergsland N(2003)Regionally localized thinning of the cerebral cortex in schizophrenia Arch Gen Psychiatry 60 878-888

Dolezal O(2002)Regional and progressive thinning of the cortical ribbon in Huntington’s disease Neurology 58 695-701

Fisher E(2014)Large-scale evaluation of ANTs and FreeSurfer cortical thickness measurements Neuroimage 99 166-179